Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Mirum Pharmaceuticals, Inc. (MIRM) had Revenue of $336.89M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$336.89M
Net Income	$-87.94M
Cost of Goods Sold	$81.64M
Gross Profit	$255.25M
Operating Expenses	$424.49M
Operating Income	$-87.61M
Non-Operating Income/Expense	$0.69M
Pre-Tax Income	$-86.91M
Normalized Pre-Tax Income	$-86.91M
Income after Taxes	$-87.94M
Income from Continuous Operations	$-87.94M
Consolidated Net Income/Loss	$-87.94M
Normalized Income after Taxes	$-87.94M
EBIT	$-87.61M
EBITDA	$-62.32M
Weighted-Average Shares Outstanding (Basic)	47.52M
Weighted-Average Shares Outstanding (Diluted)	47.52M
Earnings per Share (EPS) (Basic)	$-1.85
Earnings per Share (EPS) (Diluted)	$-1.85
Balance Sheet Financials
Current Assets	$392.79M
Property, Plant, and Equipment	$1.14M
Long-Term Assets	$277.97M
Total Assets	$670.75M
Current Liabilities	$126.55M
Long-Term Debt	$308.08M
Long-Term Liabilities	$318.56M
Total Liabilities	$445.11M
Common Equity	$225.64M
Tangible Shareholders Equity	$-24.18M
Shareholders Equity	$225.64M
Common Shares Outstanding	48.34M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$10.32M
Cash Flow from Investing Activities	$-90.12M
Cash Flow from Financial Activities	$17.70M
Beginning Cash	$286.33M
End Cash	$222.93M
Increase/Decrease in Cash	$-63.40M
Stock-Based Compensation	$48.44M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.10
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.58
Debt to Equity Ratio	1.37
Gross Margin	75.77%
Operating Margin	-26.00%
EBIT Margin	-26.00%
EBITDA Margin	-18.50%
Pre-Tax Profit Margin	-25.80%
Profit Margin	-26.10%
Free Cash Flow	$9.33M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.50
Inventory Turnover	3.64
Receiveable Turnover	4.30
Days Sales in Receivables	84.82
Return on Equity	-38.97%
Return on Tangible Equity	363.71%
Return on Assets	-13.11%
Return on Investments	-16.48%
Book Value Per Share	$4.67
Free Cash Flow per Share	$0.20
Operating Cash Flow per Share	$0.22

Data from Zacks Investment Research, Inc.